| 32.56 Real-Time Quote |  +0.33 / +1.02%Today’s Change | 21.26 Today|||52-Week Range 40.87 | +30.97% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $1.3B |
Company Description
Acorda Therapeutics, Inc. engages in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the nervous system. The company's two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. Acorda Therapeutics was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.
Employees
Shareholders
| Mutual fund holders | 58.36% |
| Other institutional | 39.17% |
| Individual stakeholders | 18.09% |
Top Executives
| Ronald Cohen, MD | President, Chief Executive Officer & Director |
| David Lawrence, MBA | Chief Financial Officer |
| Andrew R. Blight, PhD | Chief Scientific Officer |
| Anthony O. Caggiano, MD, PhD | Vice President-Research & Development |
| Enrique J. Carrazana, MD | Chief Medical Officer |
.
